Anabela Belen La Colla

Title: Anabela Belen La Colla: Pioneering Innovations in Cancer Treatment

Introduction

Anabela Belen La Colla, an accomplished inventor based in Buenos Aires, Argentina, has made significant contributions to the field of medical science. Her groundbreaking work focuses on the development of innovative treatments for cancer and hepatic fibrosis through her patented research. With one patent to her name, La Colla's expertise lies in the intricacies of molecular biology and therapeutic applications.

Latest Patents

La Colla’s notable patent is titled "TGF-receptor II isoform, fusion peptide, methods of treatment and methods in vitro." This invention revolves around an isoform of the TGF beta receptor II, which comprises a sequence of approximately 80 amino acids and lacks a transmembrane domain. The patent outlines that the isoform may include the amino acid sequence set forth in SEQ ID No. 12, or sequences demonstrating at least 85% sequence identity to SEQ ID No. 2. Additionally, the patent details a fusion peptide that consists of the TGF beta II receptor isoform fused to a ligand, which can be used in vectors to treat cancer and/or hepatic fibrosis. Furthermore, the invention includes an antibody specifically designed to bind to the soluble isoform of the TGF beta II receptor, harnessed for in vitro methodologies.

Career Highlights

Anabela Belen La Colla has collaborated with prestigious institutions throughout her career. She notably worked with the National Scientific and Technical Research Council (Consejo Nacional de Investigacion Cientifica y Tecnica) and Fundacion Articula, where her research has had a meaningful impact on advancing scientific knowledge and therapeutic strategies. This collaboration with well-respected research organizations highlights her dedication to scientific innovation and her strategic approach to overcoming health challenges.

Collaborations

Throughout her career, Anabela has had the opportunity to collaborate with notable individuals in her field, including coworkers Ana Romo and Matias Adan Preisegger. Together, they have pursued groundbreaking research that seeks to improve treatment options for debilitating diseases such as cancer and hepatic fibrosis.

Conclusion

Anabela Belen La Colla's contributions to the field of medical science through her patent on the TGF receptor II isoform and related treatments exemplify the essential role of innovation in tackling complex health challenges. With her ongoing dedication to research and collaboration within esteemed organizations, La Colla remains a key figure in the pursuit of advanced therapeutic solutions.